A Letter from Amgen about the top-line results from the MITIGATE trial

Amgen, a worldwide pioneer in biotechnology and a generous sponsor of the IgG4ward! Foundation, recently announced strongly positive results from its MITIGATE clinical trial.

This is terrific news for all of us in the IgG4-RD community. In its wake, Amgen has penned a letter to the IgG4-RD community. We are pleased to share this on Amgen's behalf.

June 5, 2024

To the community living with and supporting IgG4-Related Disease,

Today, Amgen announced positive results from the MITIGATE randomized, controlled trial for IgG4-Related Disease (RD). As an integral part of the IgG4-RD community, thank you for your partnership which helped make this clinical trial possible.

This has been a landmark study that demonstrates momentous progress in rare disease, creating the first endpoints to be evaluated in IgG4-RD and delivering data on the disease, people impacted and shared characteristics.

Our team is committed to continue to work with this community and the regulatory authorities on next steps to bring potentially transformative options to those living with IgG4-RD around the world. You have our commitment to continue to listen, learn and partner to understand the priority needs surrounding this complex disease.

We look forward to continuing our collaboration and commit to providing updates as more information is available.

Sincerely,

The Amgen Rare Disease team